{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T01:32:38Z","timestamp":1776216758096,"version":"3.50.1"},"reference-count":36,"publisher":"Scientific Scholar","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Med Res"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0971-5916.164250","type":"journal-article","created":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T05:26:31Z","timestamp":1459229191000},"page":"175","source":"Crossref","is-referenced-by-count":10,"title":["Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase"],"prefix":"10.25259","volume":"142","author":[{"given":"Hemant","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratibha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shipra","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Jasuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0971-5916.164250-1","first-page":"3358","volume-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis","author":"deLavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0971-5916.164250-2","first-page":"872","volume-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-3","first-page":"103","volume-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","author":"Bhamidipati","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"key-10.4103\/0971-5916.164250-4","first-page":"7519","volume-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0971-5916.164250-5","first-page":"2190","volume-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"key-10.4103\/0971-5916.164250-6","first-page":"876","volume-title":"Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"key-10.4103\/0971-5916.164250-7","first-page":"2381","volume-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0971-5916.164250-8","first-page":"2368","volume-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-9","first-page":"258","volume-title":"Expression of the uptake drug transporter h oct0 1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/0971-5916.164250-10","first-page":"2215","volume-title":"Clinical significance of P-glycoprotein in multidrug resistance malignancies","author":"Arceci","year":"1993","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-11","first-page":"1758","volume-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","author":"le","year":"2000","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-12","first-page":"2940","volume-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-13","first-page":"145","volume-title":"Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr\/BCrp\/ABCP1), in flavopiridol-resistant human breast cancer cells","author":"Robey","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0971-5916.164250-14","first-page":"5035","volume-title":"Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance","author":"Volk","year":"2002","journal-title":"Cancer Res"},{"key":"key-10.4103\/0971-5916.164250-15","first-page":"133","volume-title":"Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma","author":"Friedrich","year":"2004","journal-title":"In Vivo"},{"key":"key-10.4103\/0971-5916.164250-16","first-page":"4228","volume-title":"A distinct \"side population\" of cells with high drug ef\ufb02ux capacity in human tumor cells","author":"Hirschmann-Jax","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/0971-5916.164250-17","first-page":"3052","volume-title":"Expression and functional analyses of breast cancer resistance protein in lung cancer","author":"Kawabata","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0971-5916.164250-18","first-page":"83","volume-title":"Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib","author":"Chuah","year":"2009","journal-title":"Onco Targets Ther"},{"key":"key-10.4103\/0971-5916.164250-19","first-page":"3739","volume-title":"Active transport of imatinib into and out of cells: implications for drug resistance","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-20","first-page":"2447","volume-title":"Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients","author":"Guo","year":"2002","journal-title":"Leukemia"},{"key":"key-10.4103\/0971-5916.164250-21","first-page":"179","volume-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","author":"Foroni","year":"2011","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0971-5916.164250-22","unstructured":"Application note TaqMan [\u00ae ] Gene expression assays. Available from: ,\">http:\/\/www.tamu.edu\/faculty\/riggs\/BIOT602\/qPCR_efficiency.pdf, accessed on July 20, 2015."},{"key":"key-10.4103\/0971-5916.164250-23","first-page":"402","volume-title":"Analysis of relative gene expression data using realtime quantitative PCR and the 2\u2206\u2206C(T) method","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key-10.4103\/0971-5916.164250-24","first-page":"1133","volume-title":"hOCT1 and resistance to imatinib","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-25","first-page":"228","volume-title":"Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia","author":"Nardinelli","year":"2012","journal-title":"Acta Haematol"},{"key":"key-10.4103\/0971-5916.164250-26","first-page":"4041","volume-title":"Evaluation of hOCT1 expression in patients with chronic myeloid leukemia (CML) treated with imatinib in first line","author":"Mascarenhas","year":"2013","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-27","first-page":"985","volume-title":"Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)","author":"Nies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0971-5916.164250-28","first-page":"4064","volume-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","author":"White","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-29","first-page":"2761","volume-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0971-5916.164250-30","first-page":"3496","volume-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-31","first-page":"4022","volume-title":"Imatinib pharmacokinetics and its association with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0971-5916.164250-32","first-page":"1573","volume-title":"Relationship of serum imatinib trough level and response in CML patients: long term follow-up","author":"Awidi","year":"2010","journal-title":"Leuk Res"},{"key":"key-10.4103\/0971-5916.164250-33","first-page":"2614","volume-title":"Correlation of plasma trough levels of imatinib with molecular response in patients of chronic myeloid leukemia (CML): A single institution study from India","author":"Malhotra","year":"2","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0971-5916.164250-34","first-page":"1980","volume-title":"Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1","author":"Gromicho","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0971-5916.164250-35","first-page":"741","volume-title":"Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib","author":"Gromicho","year":"2013","journal-title":"Oncol Rep"},{"key":"key-10.4103\/0971-5916.164250-36","first-page":"3141","volume-title":"Interaction of imatinib with human organic ion carriers","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:56:11Z","timestamp":1751496971000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/molecular-response-to-imatinib-its-correlation-with-mrna-expression-levels-of-imatinib-influx-efflux-transporters-in-patients-with-chronic-myeloid-leukaemia-in-chronic-phase\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"alternative-id":["164250"],"URL":"https:\/\/doi.org\/10.4103\/0971-5916.164250","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}